Skip to content
HHEI

For Health Tech and EAP Partners

The clinical and equity layer your platform needs. From a partner that will not compete with you.

A multi-lens CIC contributing licensed clinical content, equity input, and clinical advisory to health tech founders, B2B health platforms, and EAP providers. The assurance layer procurement gates ask for, slotted into the product you have already built.

Book a partnership call

What we offer

OfferingDescription
Clinical content licensingMulti-condition hormonal-health modules covering endometriosis, PCOS, fibroids, fertility, perimenopause, and menopause, written for white-label use inside health tech, wellness, and EAP platforms.
Clinical advisoryFounding-clinician input into product design, content review, clinical governance, and medical-affairs positioning: the credibility layer procurement gates ask for.
Equity and cross-cultural inputBilingual and culturally-adapted content review, community-grounded user research, and equity audits that turn DEI claims into evidence.
Procurement-ready credibilityCo-branded clinical authorship, named contributing clinicians, and a Community Interest Company partner on file: the assurances enterprise buyers and NHS procurement require.
EAP-channel contentFor EAP providers extending into hormonal health: integrated modules, manager-guidance content, and clinical frameworks that complement counselling-led provision.

Multi-lens product input

Not a single named advisor. Multi-lens oversight from a team that already works together.

HHEI provides clinical, occupational, cultural, and expert-by-experience input as an integrated unit. For digital health and femtech platforms, this means the product review reflects the full breadth of users, not the perspective of a single clinical advisor.

We work with platforms at any stage: concept validation, content development, clinical accuracy review, equity audit, and ongoing advisory. HHEI does not compete with platforms it advises: we are a contributing partner, not an alternative product.

The market context

73.7%
of English women aged 16 to 55 have at least one indicator of poor hormonal health. The addressable user base.
Palmer et al., BJOG 2025 (DHSC-commissioned, n=59,332)
~2%
of public research funding dedicated to hormonal health, unchanged for a decade. The clinical-evidence gap platforms are now expected to close.
Women's Health Strategy for England, 2022

Questions

Health tech and EAP: frequently asked

  • No. HHEI is structured as a Community Interest Company specifically so we can work with the platforms that already hold the channel. We license clinical content and contribute advisory input. We do not build a competing direct-to-employer product.